Emerging data on triple agonists (GLP-1/GIP/Glucagon) suggest up to 24% body weight reduction, representing a new frontier in metabolic peptide therapy.
10 min.
April 24, 2026
Emerging data on triple agonists (GLP-1/GIP/Glucagon) suggest up to 24% body weight reduction, representing a new frontier in metabolic peptide therapy.
10 min.
April 8, 2026
Research shows AOD-9604 stimulates lipolysis and inhibits lipogenesis without affecting blood sugar or tissue growth, offering a targeted approach to fat loss.
10 min.
April 8, 2026
Participants achieved mean weight loss of 14.9% over 68 weeks compared to 2.4% with placebo. The study demonstrated sustained appetite reduction and improved cardiometabolic markers.
10 min.
April 4, 2026